Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kim M. Monti"'
Autor:
Kim M. Monti, Claudia White, Dennis J. Crouch, Melinda K. Shelby, Chad R. Borges, Matthew H. Slawson, Nicole Miller, Megan Hansen
Publikováno v:
Journal of Analytical Toxicology. 31:125-131
A qualitative liquid chromatography-tandem mass spectrometry method for the analysis of 22 sporting federation-banned anabolic agents (or their metabolite markers) and anti-estrogens in urine that are refractory to analysis by gas chromatography-mass
Publikováno v:
Journal of Analytical Toxicology. 23:535-540
Stability is an important consideration in the use of specimens for accurate determination of analyte concentrations. To determine the long-term stability for analytes routinely analyzed by mass spectrometry in this laboratory, quality-control (QC) r
Publikováno v:
Journal of Analytical Toxicology. 16:302-306
Data from five years of gas chromatographic/mass spectrometric (GC/MS) quantitation of blood, or blood and matched (i.e. concurrently collected) urine specimens, for cannabinoids have been used for two distinct evaluations. In the present study, we a
Publikováno v:
Journal of analytical toxicology. 30(1)
This study compared the ability of two on-site testing devices, Instant-View Test Card and OnTrak TesTcup Pro 5, to discriminate negative from positive urine samples for cannabinoids, cocaine metabolite, opiates, amphetamines, and benzodiazepines. Th
Publikováno v:
Journal of analytical toxicology. 16(5)
Data from five years of radioimmunoassay (RIA) screens and gas chromatographic/mass spectrometric (GC/MS) quantitation of blood, or blood and matched (i.e. concurrently collected) urine specimens for cannabinoids have been used for two distinct evalu
Publikováno v:
Journal of analytical toxicology. 15(3)
A procedure for the analysis of naltrexone and 6-beta-naltrexol in plasma and urine samples is described. The method takes advantage of the specificity of negative ion chemical ionization mass spectrometry and the resolving power of capillary column
Autor:
Mae S. Sokol, John E. Overall, Richard Perry, Spencer Ek, Phillip Adams, Kim M. Monti, Rodger L. Foltz, Magda Campbell, Eugene Roberts, Mitchell S. Nobler, Arthur M. Small
Publikováno v:
Journal of the American Academy of Child and Adolescent Psychiatry. 28(2)
The safety and efficacy of naltrexone was explored in an open acute dose range tolerance trial in 10 hospitalized autistic children, ages 3.42 to 6.50 years (mean, 5.04). Naltrexone was given in ascending doses: 0.5, 1.0, and 2.0 mg/kg/day. Behaviora